drugset / Trial / NCT02041715
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802
Phase 1
Terminated
21 enrolled
Arbutus Biopharma Corporation
United States Department of Defense · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single ascending dose (SAD) study followed by a multiple-dose cohort in healthy male and female subjects.
Timeline
- Start
- 2014-01
- Primary completion
- 2015-07
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TKM-100802 | Unknown | 0.24 mg/kg | Intravenous |